We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$19.3M
Cap. Flow %
-1.25%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.38%
2 Healthcare 10.49%
3 Financials 0.07%
4 Technology 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
126
PUT
Nektar Therapeutics
NKTR
$2.34B
$941K 0.06%
+60
New +$11.1K
HSTO
127
DELISTED
Histogen Inc. Common Stock
HSTO
$921K 0.06%
+458
New +$851K
IMUC
128
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$914K 0.06%
+89
New +$9.77K
INFI
129
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$886K 0.06%
508
-158
-24% -$3.03K
ASTX
130
PUT
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$861K 0.06%
1,015
-28
-3% -$177
ASTX
131
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$845K 0.05%
+99,703
New +$631K
ACHN
132
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$802K 0.05%
2,654
+487
+22% +$3.34K
MDGL icon
133
CALL
Madrigal Pharmaceuticals
MDGL
$12.3B
$791K 0.05%
+36
New +$7.66K
MNTA
134
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$751K 0.05%
522
– –
FBIO icon
135
CALL
Fortress Biotech
FBIO
$84.4M
$748K 0.05%
71
+38
+115% +$4.66K
XOMA
136
PUT
DELISTED
Xoma
XOMA
$742K 0.05%
+83
New +$7.54K
ASTX
137
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$740K 0.05%
873
-1,434
-62% -$9.07K
ARAY icon
138
Accuray
ARAY
$29.3M
$739K 0.05%
100,000
+57,509
+135% +$363K
FRTX
139
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$727K 0.05%
+185
New +$1.39M
VVUS
140
CALL
DELISTED
Vivus Inc
VVUS
$722K 0.05%
78
-126
-62% -$15.7K
TCRT icon
141
PUT
Alaunos Therapeutics
TCRT
$3.84M
$712K 0.05%
+12
New +$5.41K
IMNN icon
142
PUT
Imunon
IMNN
$8.25M
$710K 0.05%
+1
New +$14.8K
RIGL icon
143
Rigel Pharmaceuticals
RIGL
$847M
$710K 0.05%
+19,826
New +$724K
GERN icon
144
PUT
Geron
GERN
$880M
$697K 0.05%
+2,201
New +$3.61K
NSPH
145
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$690K 0.04%
+17,256
New +$861K
IMNN icon
146
CALL
Imunon
IMNN
$8.25M
– –
-1
Closed -$14.8K
NKTR icon
147
CALL
Nektar Therapeutics
NKTR
$2.34B
$686K 0.04%
+44
New +$8.13K
DYAX
148
DELISTED
DYAX CORPORATION
DYAX
$682K 0.04%
+99,458
New +$452K
ARIA
149
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$581K 0.04%
+31,553
New +$613K
VVUS
150
PUT
DELISTED
Vivus Inc
VVUS
$572K 0.04%
61
-59
-49% -$7.37K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.